Duration of Protection Provided by Live Attenuated Influenza Vaccine in Children
BACKGROUND:Reliable availability of influenza vaccine before October could enable the vaccination of many children who might not otherwise be vaccinated. METHODS:Available data for children were analyzed to describe protection provided by live attenuated influenza vaccine (LAIV) for greater than 5 m...
Gespeichert in:
Veröffentlicht in: | The Pediatric infectious disease journal 2008-08, Vol.27 (8), p.744-748 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BACKGROUND:Reliable availability of influenza vaccine before October could enable the vaccination of many children who might not otherwise be vaccinated.
METHODS:Available data for children were analyzed to describe protection provided by live attenuated influenza vaccine (LAIV) for greater than 5 months postvaccination.
RESULTS:Four studies conducted in children aged 6 months to 18 years were identified. Culture-confirmed efficacy against A/H1N1 and A/H3N2 strains at 9–12 months postvaccination was 77% [95% confidence interval (CI)53–89%] to 100% (95% CI68–100%) and through a second influenza season without revaccination was 56% (95% CI31–73%) and 57% (95% CI6–82%), respectively. Against B strains, 1 study demonstrated 86% (95% CI59–95%) efficacy at 5–7 months. Another study demonstrated 27% (95% CI−62% to 67%) efficacy at 9–12 months compared with 74% (95% CI39–89%) at 1 to |
---|---|
ISSN: | 0891-3668 1532-0987 |
DOI: | 10.1097/INF.0b013e318174e0f8 |